<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03257202</url>
  </required_header>
  <id_info>
    <org_study_id>HS-17-00319</org_study_id>
    <nct_id>NCT03257202</nct_id>
  </id_info>
  <brief_title>Topical Treatment and Prevalence of P. Acnes</brief_title>
  <official_title>Pre-operative Topical Treatment and the Prevalence of Propionibacterium Acnes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is about preventing surgical site infections of the shoulder. We hope to learn if
      clindamycin alone, benzoyl peroxide alone, or clindamycin and benzoyl peroxide together can
      affect growth of Propionibacterium acnes in the dermal layer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      P. acnes are skin pathogens known to cause surgical site infections despite proper
      preoperative surgical preparation. Lee et al. showed 70% growth rate of P. acnes despite the
      application of Choraprep prior to sampling. However, this study was limited as it failed to
      utilize a control group and only investigated one preparatory technique. Meanwhile, there
      remains to date no study investigating the effect of topical treatments. The purpose of this
      study is to investigate how specific topical treatments affect growth in the dermal layer. 12
      volunteers who are normal volunteers, students, or employees of USC will each receive 4 punch
      biopsies from their back above the scapular spine, with each biopsy taken from a region of
      the skin treated with a different topical (topical clindamycin alone, topical benzoyl
      peroxide alone, topical clindamycin and benzoyl peroxide together, and a control). A 3df
      overall test of the treatment indicators will test for any differences in positivity for P
      Acnes among the treatments; pairwise comparisons among the treatments will adjust for
      multiple comparisons. A two-tailed statistical test will be performed, testing at an alpha of
      0.05, and analyses will also be performed based on hemolytic subtypes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2017</start_date>
  <completion_date type="Actual">January 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Healthy volunteers</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>positive growth</measure>
    <time_frame>21 days</time_frame>
    <description>detected presence of growth of Propionibacterium acnes on bacterial culture (bacteria per mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>positive hemolysis</measure>
    <time_frame>21 days</time_frame>
    <description>detected presence of hemolysis on brucella agar (% hemolysis)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No topical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clindamycin alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical clindamycin alone using Clindamycin 1% Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benzoyl peroxide alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>topical benzoyl peroxide alone using Benzoyl Peroxide 5% Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clindamycin and benzoyl peroxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical clindamycin and topical benzoyl peroxide together using BenzaClin 5%-1% Topical Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin 1% Gel</intervention_name>
    <description>topical clindamycin</description>
    <arm_group_label>Clindamycin alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzoyl peroxide 5% gel</intervention_name>
    <description>topical benzoyl peroxide</description>
    <arm_group_label>Benzoyl peroxide alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BenzaClin 5%-1% Topical Gel</intervention_name>
    <description>Topical clindamycin and benzoyl peroxide together</description>
    <arm_group_label>Clindamycin and benzoyl peroxide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteer

          -  age &gt; 18

        Exclusion Criteria:

          -  history of antibiotic use in the last month

          -  active acne on the back

          -  non-English speakers (the study personnel do not have adequate training to converse
             and consent in other languages)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George R Hatch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keck School of Medicine of the University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Dumville JC, McFarlane E, Edwards P, Lipp A, Holmes A. Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD003949. doi: 10.1002/14651858.CD003949.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;(4):CD003949.</citation>
    <PMID>23543526</PMID>
  </reference>
  <reference>
    <citation>Mook WR, Garrigues GE. Diagnosis and Management of Periprosthetic Shoulder Infections. J Bone Joint Surg Am. 2014 Jun 4;96(11):956-965. Epub 2014 Jun 4. Review.</citation>
    <PMID>24897745</PMID>
  </reference>
  <reference>
    <citation>Matsen FA 3rd, Butler-Wu S, Carofino BC, Jette JL, Bertelsen A, Bumgarner R. Origin of propionibacterium in surgical wounds and evidence-based approach for culturing propionibacterium from surgical sites. J Bone Joint Surg Am. 2013 Dec 4;95(23):e1811-7. doi: 10.2106/JBJS.L.01733.</citation>
    <PMID>24306704</PMID>
  </reference>
  <reference>
    <citation>Lee MJ, Pottinger PS, Butler-Wu S, Bumgarner RE, Russ SM, Matsen FA 3rd. Propionibacterium persists in the skin despite standard surgical preparation. J Bone Joint Surg Am. 2014 Sep 3;96(17):1447-50. doi: 10.2106/JBJS.M.01474.</citation>
    <PMID>25187583</PMID>
  </reference>
  <reference>
    <citation>Saltzman MD, Nuber GW, Gryzlo SM, Marecek GS, Koh JL. Efficacy of surgical preparation solutions in shoulder surgery. J Bone Joint Surg Am. 2009 Aug;91(8):1949-53. doi: 10.2106/JBJS.H.00768.</citation>
    <PMID>19651954</PMID>
  </reference>
  <reference>
    <citation>Wright TE, Boyle KK, Duquin TR, Crane JK. Propionibacterium acnes Susceptibility and Correlation with Hemolytic Phenotype. Infect Dis (Auckl). 2016 Oct 9;9:39-44. eCollection 2016.</citation>
    <PMID>27773990</PMID>
  </reference>
  <reference>
    <citation>Hibbard JS. Analyses comparing the antimicrobial activity and safety of current antiseptic agents: a review. J Infus Nurs. 2005 May-Jun;28(3):194-207.</citation>
    <PMID>15912075</PMID>
  </reference>
  <reference>
    <citation>Butler-Wu SM, Burns EM, Pottinger PS, Magaret AS, Rakeman JL, Matsen FA 3rd, Cookson BT. Optimization of periprosthetic culture for diagnosis of Propionibacterium acnes prosthetic joint infection. J Clin Microbiol. 2011 Jul;49(7):2490-5. doi: 10.1128/JCM.00450-11. Epub 2011 May 4.</citation>
    <PMID>21543562</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>George F. &quot;Rick&quot; Hatch, III MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Propionibacterium Acnes</keyword>
  <keyword>Surgical Site Infection</keyword>
  <keyword>Shoulder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Yes Data will be shared as required with the USC Health Sciences Institutional Review Board. Participant data will be coded with coding identifiers kept separately by research personnel only and destroyed upon completion of the study.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>HS-17-00319</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://istar.usc.edu</doc_url>
    </study_doc>
    <study_doc>
      <doc_id>HS-17-00319</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>http://istar.usc.edu</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

